Medical School · Year 3 · General Surgery · includes a quiz and discussion video

Seminar 06: Breast Disease

Year 3: General Surgery Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Describe breast anatomy and physiology
2. Evaluate common breast complaints
3. Apply appropriate imaging modalities
4. Describe benign breast conditions
5. Understand breast cancer staging and management
6. Discuss surgical options for breast cancer

I. Breast Anatomy and Physiology

The breast is a complex glandular organ composed of 15 to 20 lobes arranged in a radial pattern, with each lobe containing lobules that produce milk and ducts that converge toward the nipple. The glandular tissue is supported by Cooper's ligaments, which are suspensory structures extending from the chest wall fascia to the skin, providing structural support and maintaining breast shape. The breast overlies the pectoralis major muscle and extends from approximately the second to the sixth rib vertically and from the sternum to the midaxillary line horizontally, with the axillary tail of Spence extending toward the axilla.

Blood supply to the breast derives primarily from the internal mammary artery, which provides approximately 60 percent of the blood flow through perforating branches, while the lateral thoracic and thoracoacromial arteries from the axillary artery supply the remaining lateral portions. The intercostal arteries also contribute to breast perfusion through lateral perforating branches. Venous drainage parallels the arterial supply, with veins draining to the internal mammary, axillary, and intercostal veins, creating potential routes for hematogenous spread of malignancy.

Lymphatic drainage of the breast follows predictable pathways that are crucial for understanding cancer spread and surgical management. The majority of lymphatic drainage, approximately 75 percent, flows to the axillary lymph nodes, which are organized into three levels defined by their relationship to the pectoralis minor muscle. Level I nodes lie lateral to the pectoralis minor, Level II nodes are posterior to the muscle, and Level III nodes are medial to it extending to the thoracic inlet. The internal mammary nodes receive drainage from the medial breast and are located along the internal mammary vessels behind the sternum.

Breast development and function are regulated by complex hormonal interactions throughout a woman's life. During puberty, estrogen stimulates ductal development while progesterone promotes lobular growth during the menstrual cycle and pregnancy. Prolactin and oxytocin are essential for lactation, with prolactin stimulating milk production and oxytocin triggering the letdown reflex. Cyclical hormonal changes during the menstrual cycle cause breast tissue to become more full and tender during the luteal phase, which is why breast examinations are optimally performed during days 7 to 10 of the cycle when hormonal influence is minimal.

<image>Panel A: Cross-sectional anatomy of the breast showing glandular lobes, Cooper's ligaments, and pectoralis major muscle. Panel B: Arterial blood supply demonstrating internal mammary perforators and lateral thoracic branches. Panel C: Lymphatic drainage pathways with axillary node levels I, II, and III labeled relative to pectoralis minor. Panel D: Hormonal influences on breast development from puberty through menopause with corresponding tissue changes.</image>

II. Breast Evaluation

Clinical breast examination is a fundamental skill that requires systematic technique and careful attention to subtle findings. The examination begins with inspection while the patient is seated, assessing for size asymmetry, skin changes such as dimpling or peau d'orange, nipple retraction or inversion, and visible masses. The patient should raise her arms and press her hands on her hips to contract the pectoral muscles, which accentuates any skin tethering. Palpation is performed with the patient supine and the ipsilateral arm raised, using the flat pads of the fingers in a systematic pattern such as concentric circles or vertical strips to ensure complete coverage.

Breast complaints require careful characterization to guide appropriate workup. A palpable mass should be assessed for size, consistency, mobility, and tenderness, with attention to whether it changes with the menstrual cycle. Breast pain may be cyclical, related to hormonal fluctuations and typically bilateral, or non-cyclical, which requires evaluation for underlying pathology. Nipple discharge characteristics are important diagnostically, with concerning features including spontaneous discharge, unilateral involvement, single duct origin, and bloody or clear serous color, while milky bilateral discharge suggests galactorrhea and green or yellow discharge is typically associated with benign conditions.

The triple assessment approach is the gold standard for evaluating breast abnormalities and combines clinical examination, imaging, and pathological sampling. All three components should provide concordant results; if they disagree, further investigation is warranted as the most concerning result should guide management. This approach achieves diagnostic accuracy exceeding 99 percent when all three modalities agree, minimizing both missed cancers and unnecessary interventions. The principle of concordance is essential because no single modality is perfectly sensitive or specific.

Age significantly influences the approach to breast evaluation due to differences in breast tissue composition and cancer risk. Women under 30 years typically have dense glandular tissue that limits mammographic sensitivity, making ultrasound the first-line imaging modality. Between ages 30 and 40, ultrasound remains primary but may be supplemented with mammography depending on clinical findings. For women over 40, mammography is the initial imaging study of choice, with ultrasound added as needed for further characterization of findings or for evaluation of dense breasts where mammographic sensitivity is reduced.

<image>Panel A: Proper patient positioning and technique for clinical breast examination in supine position. Panel B: Characteristic appearance of concerning skin changes including peau d'orange and skin dimpling. Panel C: Algorithm for triple assessment showing integration of clinical, imaging, and pathological findings. Panel D: Age-based imaging approach demonstrating ultrasound for younger women and mammography for older patients.</image>

III. Breast Imaging

Mammography remains the cornerstone of breast cancer screening and diagnostic evaluation, utilizing low-dose X-rays to detect abnormalities before they become palpable. Screening mammography is performed in asymptomatic women at regular intervals to detect early cancers, while diagnostic mammography includes additional views and magnification to characterize known abnormalities or symptoms. The sensitivity of mammography varies significantly with breast density, ranging from over 85 percent in fatty breasts to less than 50 percent in extremely dense tissue. Digital breast tomosynthesis, or 3D mammography, has improved cancer detection rates and reduced recall rates by providing multiple thin-slice images that reduce tissue overlap.

The Breast Imaging Reporting and Data System, known as BI-RADS, standardizes mammographic interpretation and provides clear management recommendations. Category 0 indicates an incomplete assessment requiring additional imaging, while Category 1 signifies a negative examination and Category 2 indicates benign findings, both recommending routine screening. Category 3 represents probably benign findings with less than 2 percent malignancy risk, warranting short-term follow-up at 6 months. Categories 4 and 5 indicate suspicious and highly suspicious findings respectively, requiring biopsy, while Category 6 is reserved for known malignancies.

Breast ultrasound serves as an essential complementary modality to mammography and is particularly valuable in specific clinical scenarios. Ultrasound excels at differentiating cystic from solid masses, with simple cysts appearing anechoic with posterior acoustic enhancement and requiring no further workup. For women with dense breasts, supplemental screening ultrasound can detect cancers occult on mammography. Ultrasound also provides guidance for interventional procedures including fine needle aspiration and core needle biopsy, allowing real-time visualization of needle placement.

Magnetic resonance imaging offers the highest sensitivity for breast cancer detection, approaching 95 to 100 percent, but with lower specificity leading to higher false-positive rates. MRI is indicated for high-risk screening in women with greater than 20 percent lifetime cancer risk, including BRCA mutation carriers and those with prior chest radiation. Preoperative MRI may assess the extent of known cancer and detect additional occult tumors, though its impact on surgical outcomes remains debated. MRI is also valuable for evaluating breast implant integrity and searching for occult primary tumors in patients presenting with axillary metastases.

<image>Panel A: Normal mammographic appearance comparing fatty and dense breast tissue patterns. Panel B: BI-RADS classification examples showing Category 2 benign calcifications through Category 5 spiculated mass. Panel C: Ultrasound images demonstrating simple cyst with posterior enhancement versus suspicious solid mass. Panel D: MRI appearance of breast cancer showing arterial enhancement and washout kinetics.</image>

IV. Benign Breast Conditions

Fibroadenoma is the most common benign breast tumor, occurring predominantly in women between 15 and 35 years of age. These tumors present as firm, rubbery, well-circumscribed masses that are mobile and nontender, often described as feeling like a marble within the breast. On ultrasound, fibroadenomas appear as oval, homogeneous, well-defined masses with smooth borders, and they may contain calcifications in older women. Management is typically conservative with observation for small stable lesions, while excision is recommended for rapidly growing masses, those larger than 2 to 3 centimeters, or when causing significant patient anxiety.

Breast cysts are fluid-filled structures that commonly occur in women during their 30s and 40s, often associated with fibrocystic changes of the breast. Simple cysts are benign and appear on ultrasound as anechoic round or oval structures with posterior acoustic enhancement and imperceptible walls. Complex cysts containing internal debris, thick walls, or solid components require further evaluation and possible aspiration or biopsy to exclude malignancy. Fibrocystic changes represent a spectrum of benign alterations including cyst formation, fibrosis, and epithelial hyperplasia, typically presenting with cyclical bilateral breast pain and nodularity that fluctuates with the menstrual cycle.

Fat necrosis results from trauma or surgical intervention to the breast and can clinically and radiographically mimic malignancy. Patients may present with a firm, fixed mass that may be associated with skin thickening or retraction. Imaging findings are variable, ranging from oil cysts with characteristic calcified rims to dense irregular masses indistinguishable from cancer. When imaging findings are suspicious, core needle biopsy is necessary to establish the diagnosis, revealing lipid-laden macrophages, foamy histiocytes, and inflammatory changes rather than malignant cells.

Breast infections occur in two distinct clinical contexts with different etiologies and management approaches. Lactational mastitis affects breastfeeding women, typically caused by Staphylococcus aureus entering through nipple fissures, and is treated with antibiotics effective against gram-positive organisms while encouraging continued nursing. Breast abscesses require drainage, either through needle aspiration with ultrasound guidance or incision and drainage for larger collections. Non-lactational breast infections should raise concern for underlying malignancy, particularly inflammatory breast cancer, and require careful evaluation including imaging and biopsy if findings persist despite appropriate treatment.

<image>Panel A: Ultrasound appearance of a classic fibroadenoma showing well-circumscribed oval homogeneous mass. Panel B: Comparison of simple cyst versus complex cyst on ultrasound imaging. Panel C: Mammographic appearance of fat necrosis showing calcified oil cyst and variable presentations. Panel D: Clinical appearance of lactational mastitis with associated erythema and ultrasound of breast abscess requiring drainage.</image>

V. Nipple Discharge

Nipple discharge evaluation begins with characterizing the discharge to determine whether it represents a concerning finding requiring further investigation. Pathologic discharge is typically spontaneous, unilateral, from a single duct, and bloody or clear in color, while physiologic discharge is usually bilateral, multiductal, and requires expression to elicit. Green, yellow, or brown discharge is generally associated with benign conditions such as duct ectasia or fibrocystic changes. The ability to identify a trigger point on the areola that produces discharge helps localize the involved duct for potential surgical excision.

The differential diagnosis of nipple discharge varies based on discharge characteristics and patient demographics. Milky bilateral discharge, or galactorrhea, suggests hyperprolactinemia and warrants evaluation of prolactin levels and possible pituitary imaging. Intraductal papilloma is the most common cause of spontaneous bloody nipple discharge and consists of a benign epithelial tumor within a breast duct. Ductal carcinoma in situ may also present with bloody discharge, emphasizing the importance of thorough evaluation. Duct ectasia, involving dilation and inflammation of subareolar ducts, typically produces green or brown discharge in perimenopausal women.

Diagnostic evaluation of nipple discharge proceeds systematically to identify the underlying cause. Physical examination should note the character, color, and duct of origin of the discharge. Mammography provides baseline imaging and may reveal associated calcifications or masses. Breast ultrasound can visualize dilated ducts and intraductal lesions. Ductography, involving injection of contrast into the affected duct followed by mammography, can localize filling defects but has been largely replaced by MRI, which offers superior sensitivity for detecting papillomas and malignancy without radiation.

Management of nipple discharge depends on the underlying etiology identified through workup. Intraductal papilloma is definitively treated with central duct excision or microdochectomy, which removes the involved duct while preserving the remaining breast tissue. Duct ectasia may be managed conservatively with warm compresses and reassurance, though persistent symptoms may warrant duct excision. Any discharge associated with suspicious imaging findings or atypical cytology requires surgical excision to exclude malignancy. Galactorrhea is managed by addressing the underlying hyperprolactinemia, which may involve discontinuing causative medications or treating a prolactinoma.

<image>Panel A: Technique for expressing nipple discharge and identifying the trigger point on the areola. Panel B: Characteristic appearance of bloody versus green discharge with associated conditions. Panel C: Ductogram image showing filling defect consistent with intraductal papilloma. Panel D: Surgical specimen from central duct excision showing papilloma within dilated duct.</image>

VI. Breast Cancer Risk Factors

Multiple risk factors contribute to breast cancer development, with age being the most significant non-modifiable factor as risk increases progressively throughout life. Genetic mutations, particularly in BRCA1 and BRCA2 genes, confer dramatically elevated lifetime risks of 50 to 85 percent compared to the general population risk of approximately 12 percent. A history of breast cancer increases the risk of developing a second primary tumor by 3 to 4 times. Proliferative breast lesions also elevate risk, with atypical ductal or lobular hyperplasia conferring a 4 to 5 fold increase, while lobular carcinoma in situ represents both a risk marker and precursor lesion with 8 to 10 fold elevated bilateral breast cancer risk.

Hormonal and reproductive factors significantly influence breast cancer risk through their effects on cumulative estrogen exposure. Early menarche before age 12 and late menopause after age 55 both increase risk by extending the duration of ovarian hormone exposure. Nulliparity and late age at first pregnancy are associated with elevated risk, while breastfeeding provides a protective effect that increases with duration. Combined hormone replacement therapy, particularly estrogen plus progestin formulations, increases breast cancer risk, with the magnitude of risk related to duration of use, though risk decreases after discontinuation.

Genetic testing has become increasingly important in identifying women at highest risk who may benefit from intensive surveillance or risk-reducing interventions. BRCA1 mutations are associated with triple-negative breast cancer and significantly elevated ovarian cancer risk, while BRCA2 mutations more commonly produce estrogen receptor-positive tumors and are the predominant cause of male breast cancer. Additional genes including PALB2, TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), and CDH1 confer moderate to high breast cancer risks. Criteria for genetic testing include early-onset breast cancer, triple-negative histology, bilateral disease, male breast cancer, family history of breast or ovarian cancer, and Ashkenazi Jewish ancestry.

Risk reduction strategies are available for women identified as high-risk through genetic testing or risk assessment models. Chemoprevention with selective estrogen receptor modulators such as tamoxifen or raloxifene reduces breast cancer incidence by approximately 50 percent in high-risk women. Aromatase inhibitors, including anastrozole and exemestane, offer similar risk reduction for postmenopausal women with potentially more favorable side effect profiles. Prophylactic bilateral mastectomy reduces breast cancer risk by 90 to 95 percent and is an option for BRCA mutation carriers who desire definitive risk reduction. Prophylactic oophorectomy in BRCA carriers reduces both ovarian cancer risk and breast cancer risk, particularly when performed before age 40.

<image>Panel A: Graph showing increasing breast cancer risk with age from 30 to 80 years. Panel B: Pedigree diagram illustrating hereditary breast and ovarian cancer syndrome pattern. Panel C: Comparison of lifetime breast cancer risk among general population, BRCA2, and BRCA1 carriers. Panel D: Summary of risk-reducing interventions including surveillance, chemoprevention, and prophylactic surgery with relative risk reductions.</image>

VII. Breast Cancer Types

In situ carcinomas represent proliferations of malignant cells confined within the basement membrane without invasion into surrounding stroma. Ductal carcinoma in situ (DCIS) is a heterogeneous condition that varies in grade, extent, and risk of progression to invasive cancer, estimated at 25 to 50 percent over time if untreated. DCIS is typically detected mammographically as calcifications and is managed with excision to negative margins, with radiation reducing local recurrence by approximately 50 percent and endocrine therapy providing additional benefit for hormone receptor-positive disease. Lobular carcinoma in situ (LCIS) is considered primarily a risk marker rather than a direct precursor, conferring bilateral elevated risk of approximately 1 percent per year, and is managed with enhanced surveillance or risk-reducing strategies.

Invasive breast cancers are classified histologically, with invasive ductal carcinoma of no special type comprising 70 to 80 percent of cases. Invasive lobular carcinoma accounts for 10 to 15 percent and is characterized by single-file growth pattern, E-cadherin loss, and a propensity for multifocal and bilateral disease. Special histologic types with favorable prognosis include mucinous (colloid), tubular, and medullary carcinomas, which together represent less than 10 percent of cases. Inflammatory breast cancer is a clinically defined aggressive variant characterized by rapid onset of erythema, warmth, and peau d'orange involving at least one-third of the breast, caused by dermal lymphatic invasion.

Molecular subtyping has revolutionized breast cancer classification and treatment selection by categorizing tumors based on estrogen receptor (ER), progesterone receptor (PR), and HER2 status. Luminal A tumors are ER-positive, PR-positive, HER2-negative with low proliferation index and have excellent prognosis with endocrine therapy alone. Luminal B tumors are hormone receptor-positive but with higher proliferation or HER2-positivity, often requiring chemotherapy in addition to endocrine therapy. HER2-enriched tumors are hormone receptor-negative and HER2-positive, benefiting dramatically from HER2-targeted therapies such as trastuzumab. Triple-negative breast cancers lack all three receptors and require chemotherapy, though immunotherapy has recently shown benefit for PD-L1 positive tumors.

Special clinical presentations of breast cancer require recognition for appropriate management. Inflammatory breast cancer presents with rapid onset of diffuse breast erythema, edema, and warmth without a discrete mass, often mimicking mastitis but failing to respond to antibiotics. Paget's disease of the nipple manifests as eczematous changes of the nipple-areolar complex with associated underlying DCIS or invasive cancer in over 95 percent of cases. Phyllodes tumors are rare fibroepithelial neoplasms with a spectrum from benign to malignant, characterized by rapid growth and leaf-like projections on histology, treated with wide local excision to negative margins without lymph node dissection.

<image>Panel A: Mammographic appearance of DCIS showing clustered pleomorphic calcifications. Panel B: Histologic comparison of invasive ductal carcinoma versus invasive lobular carcinoma growth patterns. Panel C: Clinical photograph of inflammatory breast cancer showing characteristic peau d'orange and erythema. Panel D: Molecular subtypes of breast cancer with receptor profiles and treatment implications.</image>

VIII. Breast Cancer Staging

The TNM staging system for breast cancer incorporates tumor size, lymph node involvement, and presence of metastases to stratify prognosis and guide treatment decisions. T1 tumors measure 2 centimeters or less in greatest dimension, T2 tumors are greater than 2 to 5 centimeters, T3 tumors exceed 5 centimeters, and T4 tumors involve the chest wall or skin regardless of size. Tis designates carcinoma in situ, while T4 subcategories specify chest wall invasion (T4a), skin ulceration or satellite nodules (T4b), both (T4c), or inflammatory carcinoma (T4d). Accurate T staging requires pathological measurement of invasive tumor size, excluding DCIS component.

Nodal staging reflects the extent of regional lymph node involvement, which remains one of the most powerful prognostic factors in breast cancer. N0 indicates no regional lymph node metastases, while N1 designates metastases in 1 to 3 axillary lymph nodes. N2 includes 4 to 9 involved axillary nodes or clinically detected internal mammary involvement without axillary disease. N3 encompasses 10 or more axillary nodes, infraclavicular involvement, or combined internal mammary and axillary disease. The method of detection matters, with isolated tumor cells less than 0.2 millimeters classified differently than micrometastases (0.2 to 2 millimeters) and macrometastases (greater than 2 millimeters).

Stage groupings combine TNM parameters to categorize patients into prognostic cohorts. Stage 0 represents carcinoma in situ with no nodal involvement. Stage I encompasses small tumors (T1) without nodal metastases, with excellent prognosis exceeding 95 percent 5-year survival. Stage II includes larger tumors (T2-T3) or limited nodal involvement (N1). Stage III represents locally advanced disease with extensive nodal involvement or direct tumor extension, while Stage IV indicates distant metastatic disease regardless of the primary tumor or nodal status.

The 8th edition AJCC staging system incorporates biological factors beyond anatomic staging to create prognostic stage groups. Tumor grade, estrogen receptor status, progesterone receptor status, HER2 status, and multigene assay results (when applicable) modify the anatomic stage to better predict outcome. For example, a small hormone receptor-positive, HER2-negative tumor with favorable Oncotype DX recurrence score may be downstaged prognostically despite nodal involvement. This prognostic staging system recognizes that tumor biology significantly influences outcomes beyond anatomic extent, particularly for hormone receptor-positive cancers where endocrine therapy substantially improves prognosis.

<image>Panel A: Diagram illustrating T stage categories based on tumor size from Tis through T4. Panel B: Axillary lymph node levels with N stage designations based on number of involved nodes. Panel C: Summary table of stage groupings from 0 through IV with corresponding TNM combinations. Panel D: Comparison of anatomic versus prognostic staging incorporating biomarker status.</image>

IX. Surgical Treatment

Breast-conserving therapy, consisting of lumpectomy with radiation therapy, has become the standard surgical approach for most early-stage breast cancers, offering equivalent survival to mastectomy. The surgical goal is complete excision of the tumor with negative margins, defined as no ink on tumor for invasive cancer and 2 millimeters for DCIS. Candidates for breast conservation include patients with tumors that can be excised with acceptable cosmetic result, absence of multicentric disease, ability to undergo radiation therapy, and patient preference for breast preservation. Contraindications include multicentric disease, diffuse suspicious calcifications, prior breast radiation, pregnancy during the radiation period, and connective tissue disorders predisposing to radiation toxicity.

Mastectomy remains indicated for specific clinical scenarios and patient preferences, with several variations of the procedure available. Simple mastectomy removes all breast tissue including the nipple-areolar complex while preserving the pectoral muscles. Skin-sparing mastectomy preserves the native breast skin envelope while removing breast tissue and nipple, facilitating immediate reconstruction. Nipple-sparing mastectomy further preserves the nipple-areolar complex when oncologically safe, typically for risk-reducing surgery or peripherally located cancers without nipple involvement. Modified radical mastectomy adds Level I and II axillary lymph node dissection to simple mastectomy and is performed when axillary dissection is indicated.

Axillary surgery has evolved significantly with sentinel lymph node biopsy (SLNB) replacing routine axillary lymph node dissection (ALND) for staging clinically node-negative patients. SLNB identifies the first lymph node(s) receiving drainage from the tumor using radioactive tracer, blue dye, or both, with the principle that if sentinel nodes are negative, skip metastases are extremely rare. The ACOSOG Z0011 trial demonstrated that women with 1 to 2 positive sentinel nodes undergoing lumpectomy with whole-breast radiation may safely omit ALND, significantly reducing morbidity including lymphedema, shoulder dysfunction, and numbness.

Breast reconstruction options are available for women undergoing mastectomy, categorized as implant-based or autologous tissue techniques. Implant reconstruction may be single-stage (direct-to-implant) or two-stage with initial tissue expander placement followed by exchange to permanent implant. Autologous reconstruction uses the patient's own tissue, including transverse rectus abdominis myocutaneous (TRAM) flap, deep inferior epigastric perforator (DIEP) flap, or latissimus dorsi flap. Reconstruction may be immediate at the time of mastectomy or delayed, with immediate reconstruction increasingly preferred for improved cosmetic outcomes and psychological benefits without adverse oncologic effects.

<image>Panel A: Surgical specimen from lumpectomy with orientation markers and margin assessment. Panel B: Comparison of mastectomy types from simple through skin-sparing and nipple-sparing approaches. Panel C: Sentinel lymph node biopsy technique showing injection of tracer and gamma probe detection. Panel D: Breast reconstruction options including implant-based and DIEP flap autologous reconstruction.</image>

X. Systemic Therapy

Chemotherapy plays a critical role in breast cancer treatment, administered in either the neoadjuvant setting before surgery or the adjuvant setting after surgery. Neoadjuvant chemotherapy offers advantages including tumor downstaging to enable breast conservation, assessment of tumor response providing prognostic information, and early treatment of micrometastatic disease. Achieving a pathologic complete response (pCR), defined as no residual invasive disease in breast and lymph nodes, correlates with improved long-term outcomes, particularly for triple-negative and HER2-positive subtypes. Common regimens include anthracycline-based combinations (AC-T: doxorubicin, cyclophosphamide, paclitaxel) and non-anthracycline alternatives (TC: docetaxel, cyclophosphamide), with dose-dense scheduling improving outcomes for high-risk patients.

Endocrine therapy is the backbone of treatment for hormone receptor-positive breast cancer, which comprises approximately 70 percent of all cases. Tamoxifen, a selective estrogen receptor modulator, is effective in both premenopausal and postmenopausal women, reducing recurrence risk by approximately 50 percent when given for 5 to 10 years. Aromatase inhibitors (anastrozole, letrozole, exemestane) are preferred for postmenopausal women, blocking peripheral estrogen synthesis. For premenopausal high-risk patients, ovarian suppression combined with an aromatase inhibitor or tamoxifen provides superior outcomes. Extended adjuvant therapy beyond 5 years further reduces late recurrence risk for patients with node-positive or other high-risk features.

Targeted therapies have transformed outcomes for specific breast cancer subtypes defined by molecular characteristics. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, combined with chemotherapy dramatically improves survival for HER2-positive cancers, with the addition of pertuzumab providing incremental benefit. For patients with residual disease after neoadjuvant therapy, ado-trastuzumab emtansine (T-DM1) improves outcomes over continued trastuzumab. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy have become standard for advanced hormone receptor-positive disease. PARP inhibitors offer benefit for BRCA-mutated breast cancers by exploiting deficient DNA repair mechanisms.

Radiation therapy is an integral component of breast cancer treatment, required after lumpectomy to reduce local recurrence from approximately 30 percent to less than 10 percent. Post-mastectomy radiation is indicated for high-risk features including tumor size greater than 5 centimeters, involvement of 4 or more lymph nodes, or positive surgical margins. Regional nodal irradiation encompasses the supraclavicular, infraclavicular, and internal mammary basins depending on nodal involvement and tumor location. Hypofractionated regimens delivering larger daily doses over fewer treatments have demonstrated equivalent efficacy and safety compared to conventional fractionation, offering improved convenience for patients.

<image>Panel A: Timeline comparing neoadjuvant versus adjuvant chemotherapy sequencing with surgery. Panel B: Mechanism of action diagram for endocrine therapy including tamoxifen and aromatase inhibitors. Panel C: HER2-targeted therapy mechanisms showing trastuzumab binding to HER2 receptor and pertuzumab blocking dimerization. Panel D: Radiation therapy fields demonstrating whole-breast, chest wall, and regional nodal treatment volumes.</image>

Summary

• Breast anatomy: 15-20 lobes draining to nipple; lymphatics primarily to axilla with levels defined by pectoralis minor
• Triple assessment: clinical exam, imaging, and pathology must be concordant for reliable diagnosis
• BI-RADS: standardized mammography reporting from 0 to 6 guiding management recommendations
• Fibroadenoma: young women; mobile, well-circumscribed mass; observe small stable lesions
• Bloody nipple discharge: concerning finding requiring evaluation for papilloma or cancer
• BRCA mutations: 50-85% lifetime breast cancer risk; consider prophylactic surgery or enhanced surveillance
• Molecular subtypes: Luminal A/B, HER2-enriched, and triple-negative guide systemic therapy selection
• Breast-conserving therapy: lumpectomy plus radiation provides equivalent survival to mastectomy
• SLNB: standard for clinically negative axilla; ALND may be omitted with limited positive nodes per Z0011
• Endocrine therapy: tamoxifen or aromatase inhibitors for 5-10 years reduce recurrence in HR-positive disease

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown